PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Golimumab - Non-radiographic axial spondyloarthritis

PAD Profile : Golimumab - Non-radiographic axial spondyloarthritis

Keywords :
Biologic, anti-TNF, TNF-alpha, monoclonal antibody, cytokine modulator, nrAS, nr-AS
Brand Names Include :
Simponi

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Subcutaneous injection (sc)
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Type
Document
Review Date

Committee Recommendations

Date
Committee Name
Narrative
06 December 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated axial spondyloarthritis pathway.

Treatment pathway is available on separate guidelines page.

26 March 2018
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The Prescribing Clinical Network recommends Golimumab as a treatment option for non-radiographic axial spondyloarthritis in line with NICE TA497 (January 2018). Golimumab for this indication will be considered as RED on the traffic light status (treatment should be initiated and continued by specialist clinicians) Golimumab is a payment by results excluded drug and specialists will be required to notify commissioners of initiation and response to treatment using the tick box proformas available on the blueteq system.

Associated BNF Codes

10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More